PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25712887-0 2015 Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Flurbiprofen 59-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 11-17 27298492-2 2016 Considering the paucity of data on the polymorphisms of CYP2C9 in Western Indian population, the present study was conducted to evaluate the prevalence of CYP2C9 polymorphisms (*1, *2 and *3) and correlate it with the activity using flurbiprofen (FLB) as a probe drug. Flurbiprofen 233-245 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 155-161 27298492-2 2016 Considering the paucity of data on the polymorphisms of CYP2C9 in Western Indian population, the present study was conducted to evaluate the prevalence of CYP2C9 polymorphisms (*1, *2 and *3) and correlate it with the activity using flurbiprofen (FLB) as a probe drug. Flurbiprofen 247-250 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 155-161 25712887-1 2015 The aim of this study was to investigate the impact of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen and its metabolite. Flurbiprofen 103-115 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 55-61 25712887-5 2015 AUCinf of flurbiprofen was significantly higher and its clearance was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. Flurbiprofen 10-22 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 97-103 25712887-5 2015 AUCinf of flurbiprofen was significantly higher and its clearance was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. Flurbiprofen 10-22 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 140-146 25712887-6 2015 The AUC ratio of 4"-hydroxyflurbiprofen to flurbiprofen was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. Flurbiprofen 27-39 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 87-93 25712887-6 2015 The AUC ratio of 4"-hydroxyflurbiprofen to flurbiprofen was significantly lower in the CYP2C9*1/*3 individuals than in those with CYP2C9*1/*1. Flurbiprofen 27-39 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 130-136 25712887-7 2015 These results indicate that the individuals carrying of CYP2C9*3 have significant reduction in flurbiprofen metabolism. Flurbiprofen 95-107 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 56-62 25144335-0 2015 Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Flurbiprofen 59-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 10-16 25875957-0 2015 Correction: CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. Flurbiprofen 109-121 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 12-18 25775139-0 2015 CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug. Flurbiprofen 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 25144335-5 2015 This study provided the most comprehensive data on the enzymatic activities of all reported CYP2C9 variants in the Chinese population with regard to the commonly used non-steroidal anti-inflammatory drug, flurbiprofen (FP). Flurbiprofen 205-217 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 92-98 22547083-5 2012 METHODS: We assayed the activities of CYP2C9.1, CYP2C9.2, and CYP2C9.3 to metabolize diclofenac, flurbiprofen, and tolbutamide using a wild type or one of four POR variants (Q153R, A287P, R457H, and A503V). Flurbiprofen 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 38-44 24423593-2 2014 P-gp (fexofenadine) and CYP-specific substrates (caffeine for CYP1A2, bupropion for CYP2B6, flurbiprofen for CYP2C9, omeprazole for CYP2C19, dextromethorphan for CYP2D6 and midazolam for CYP3A4) and their metabolites were extracted from DBS (10 microl) using methanol. Flurbiprofen 92-104 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 109-115 22943633-9 2013 In the study of flurbiprofen (CYP2C9 substrate), the positive control inhibitor fluconazole significantly increased flurbiprofen AUC (GMR = 1.71), but BBJ had no significant effect (GMR = 1.03). Flurbiprofen 16-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 22943633-9 2013 In the study of flurbiprofen (CYP2C9 substrate), the positive control inhibitor fluconazole significantly increased flurbiprofen AUC (GMR = 1.71), but BBJ had no significant effect (GMR = 1.03). Flurbiprofen 116-128 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 23737517-4 2013 The pharmacokinetics of the probe drug cocktail (flurbiprofen/fexofenadine) were altered, with formation clearance of flurbiprofen (CYP2C9 function) lower in our patient versus the average value in our study cohort, suggesting a reduction in activity. Flurbiprofen 118-130 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 132-138 22547083-5 2012 METHODS: We assayed the activities of CYP2C9.1, CYP2C9.2, and CYP2C9.3 to metabolize diclofenac, flurbiprofen, and tolbutamide using a wild type or one of four POR variants (Q153R, A287P, R457H, and A503V). Flurbiprofen 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 22547083-5 2012 METHODS: We assayed the activities of CYP2C9.1, CYP2C9.2, and CYP2C9.3 to metabolize diclofenac, flurbiprofen, and tolbutamide using a wild type or one of four POR variants (Q153R, A287P, R457H, and A503V). Flurbiprofen 97-109 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 48-54 19074529-5 2009 The other flavonoids exert competitive inhibition through interaction with the substrate binding site of CYP2C9 accessed by flurbiprofen. Flurbiprofen 124-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 105-111 21223634-8 2011 However, one subject"s data was suggestive of being poor metabolizer of flurbiprofen which supports the presence of CYP2C9 polymorphism contributing to inter-individual differences in flurbiprofen disposition. Flurbiprofen 72-84 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 116-122 21223634-8 2011 However, one subject"s data was suggestive of being poor metabolizer of flurbiprofen which supports the presence of CYP2C9 polymorphism contributing to inter-individual differences in flurbiprofen disposition. Flurbiprofen 184-196 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 116-122 20215413-4 2010 CYP2C9-mediated metabolism of S-naproxen and S-flurbiprofen was inhibited up to 80% by coincubation with CYP3A4, although K(m) values were unchanged. Flurbiprofen 45-59 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 20167000-9 2009 Currently, there are three X-ray structures of the human CYP2C9 in Protein Database (PDB): one ligand-free protein (1OG2), and two in complex with S-warfarin (1OG5) or flurbiprofen (1R9O). Flurbiprofen 168-180 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 57-63 20167001-6 2009 Typical substrates of CYP2C9 such as celecoxib, ibuprofen, flurbiprofen, and diclofenac are relatively small, lipophilic and contain acidic groupings with pK(a) values in the range 3.8-8.1 which will be ionized at physiological pH. Flurbiprofen 59-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 22-28 19448135-6 2009 CYP2D6 coincubation inhibited CYP2C9-mediated (S)-flurbiprofen metabolism in a protein concentration-dependent manner. Flurbiprofen 46-62 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 19448135-8 2009 Spectral binding studies revealed a 20-fold increase in the K(S) of CYP2C9 toward (S)-flurbiprofen in the presence of CYP2D6. Flurbiprofen 82-98 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 68-74 19258521-5 2009 This pattern of effects differs substantially from that found previously for (S)-warfarin and (S)-flurbiprofen metabolism, suggesting that these three ligands bind within discrete locations in the CYP2C9 active site. Flurbiprofen 94-110 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 197-203 18237107-2 2008 The molecular alignment program ROCS was used with the query molecule flurbiprofen as a basis for predicting the correct active site orientation of the CYP2C9 database molecules. Flurbiprofen 70-82 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 152-158 18922023-1 2008 The two published crystal structures of cytochrome P450 2C9, complexed with ( S)-warfarin or flurbiprofen, implicate a cluster of three active site phenylalanine residues (F100, F114, F476) in ligand binding. Flurbiprofen 93-105 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 40-59 18922023-3 2008 To elucidate the importance of CYP2C9"s active site phenylalanines on substrate binding, orientation, and catalytic turnover, a series of leucine and tryptophan mutants were constructed and their interactions with ( S)-warfarin and ( S)-flurbiprofen examined. Flurbiprofen 232-249 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 31-37 18378563-2 2008 Previous in vitro work has demonstrated that genotype-dependent inhibition of CYP2C9 mediated flurbiprofen metabolism, suggesting the possibility of genotype-dependent inhibition interactions in vivo. Flurbiprofen 94-106 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 78-84 15170358-1 2004 Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4"-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Flurbiprofen 38-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-19 17960328-0 2007 Effective virtual screening protocol for CYP2C9 ligands using a screening site constructed from flurbiprofen and S-warfarin pockets. Flurbiprofen 96-108 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 41-47 17960328-1 2007 An effective virtual screening protocol was developed against an extended active site of CYP2C9, which was derived from X-ray structures complexed with flubiprofen and S-warfarin. Flurbiprofen 152-163 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 89-95 16118328-8 2005 In contrast, CYP2C9 genotype is expected to impact the clearance of ibuprofen, indomethacin, flurbiprofen, celecoxib, valdecoxib, lornoxicam, tenoxicam, meloxicam, and piroxicam. Flurbiprofen 93-105 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 15955872-3 2005 Although benzbromarone inhibited CYP2C9.1 activity as expected, CYP2C9.3-mediated flurbiprofen 4"-hydroxylation was activated in the presence of benzbromarone. Flurbiprofen 82-94 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 64-70 15170358-2 2004 Previous spectral binding studies have demonstrated that the binding of flurbiprofen with CYP2C9 is increased (decrease in K(S)) by the presence of dapsone. Flurbiprofen 72-84 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 90-96 15170358-9 2004 Molecular modeling studies were also performed to corroborate the relative orientations of flurbiprofen and dapsone in the active site of CYP2C9. Flurbiprofen 91-103 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 138-144 15170358-10 2004 Shift of the 4" proton of flurbiprofen closer to the heme iron of CYP2C9 in the presence of dapsone may play a role in activation. Flurbiprofen 26-38 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 66-72 17054666-0 2007 Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Flurbiprofen 14-26 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 65-71 16928789-7 2006 In addition, when (S)-flurbiprofen was used as a substrate probe to determine CYP2C9 inhibition with a set of 12 inhibitors, decreased inhibition potency was observed across 11 of those inhibitors in the RECO purified, reconstituted enzyme compared with the Supersomes baculovirus microsomal preparation and pooled human liver microsomes. Flurbiprofen 18-34 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 78-84 16952492-1 2006 BACKGROUND: We have previously shown that flurbiprofen metabolism to 4"-hydroxyflurbiprofen provides an in vivo measure of cytochrome P450 (CYP) 2C9 activity. Flurbiprofen 42-54 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 123-148 15181000-0 2004 The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. Flurbiprofen 58-70 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 23-42 15170358-1 2004 Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4"-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Flurbiprofen 38-50 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 21-27 15170358-1 2004 Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4"-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Flurbiprofen 147-159 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-19 15170358-1 2004 Cytochrome P450 2C9 (CYP2C9)-mediated flurbiprofen 4"-hydroxylation is activated by the presence of dapsone resulting in reduction of the K(m) for flurbiprofen hydroxylation and an increase in V(m). Flurbiprofen 147-159 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 21-27 33336382-7 2021 In addition, metamizole weakly induced CYP2C9 (decrease in the flurbiprofen AUC by 22%) and moderately CYP2C19 (decrease in the omeprazole AUC by 66%) but did not alter CYP2D6 activity. Flurbiprofen 63-75 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 39-45 12698304-4 2003 RESULTS: CYP2C9 genotype was a significant predictor of flurbiprofen metabolism and accounted for 59% of the variability in flurbiprofen AUC(0- infinity ), and approximately 50% of the variability in flurbiprofen oral clearance, formation clearance to 4"-hydroxyflurbiprofen, and the 0 to 24-h urinary metabolic ratio of flurbiprofen to 4"-hydroxyflurbiprofen. Flurbiprofen 124-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 9-15 12698304-5 2003 Flurbiprofen AUC(0- infinity )was significantly higher and all measures of flurbiprofen clearance were significantly lower in the CYP2C9*1/*3 individuals than in those with *1/*1. Flurbiprofen 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 130-136 12698304-5 2003 Flurbiprofen AUC(0- infinity )was significantly higher and all measures of flurbiprofen clearance were significantly lower in the CYP2C9*1/*3 individuals than in those with *1/*1. Flurbiprofen 75-87 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 130-136 12698304-7 2003 CONCLUSIONS: CYP2C9 genotype is a significant predictor of flurbiprofen disposition in humans by altering CYP2C9-mediated metabolism and reducing systemic clearance. Flurbiprofen 59-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 13-19 12698304-7 2003 CONCLUSIONS: CYP2C9 genotype is a significant predictor of flurbiprofen disposition in humans by altering CYP2C9-mediated metabolism and reducing systemic clearance. Flurbiprofen 59-71 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 106-112 12559973-2 2003 Kinetic studies suggested that dapsone activated CYP2C9-mediated flurbiprofen 4(")-hydroxylation by decreasing the K(m) (alpha=0.2) and increasing the V(max) (beta=1.9). Flurbiprofen 65-77 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 12559973-5 2003 In the presence of dapsone, the spectral binding constant (K(s)) for flurbiprofen was reduced from 14.1 to 2.1 microM, while in the presence of N-hydroxydapsone, the K(s) remained unchanged (14.0 microM), which suggests that dapsone causes an increase in the affinity of flurbiprofen for CYP2C9, whereas N-hydroxydapsone does not. Flurbiprofen 69-81 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 288-294 11408370-4 2001 Dapsone increased the Michaelis-Menten-derived V(max) of flurbiprofen 4"-hydroxylation from 12.6 to 20.6 pmol/min/pmol P450, and lowered its K(m) from 28.9 to 10.0 microM, suggesting that dapsone activates CYP2C9-mediated flurbiprofen metabolism without displacing flurbiprofen from the active site, supporting a two-site model describing activation. Flurbiprofen 57-69 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 206-212 11129071-8 2000 This method provides a sensitive and specific assay for the detection of flurbiprofen and 4"-hydoxyflurbiprofen in urine and plasma and is suitable for use in in vivo studies evaluating the regulation of CYP2C9 activity. Flurbiprofen 73-85 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 204-210 9521735-5 1998 7, 8-Benzoflavone activation of phenanthrene metabolism by CYP3A4 and dapsone activation of flurbiprofen and naproxen metabolism by CYP2C9 were also observed. Flurbiprofen 92-104 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 132-138 35168147-5 2022 Flurbiprofen/naproxen and piroxicam are located in the active site and the primary binding site of CYP2C9, respectively. Flurbiprofen 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 99-105 15130760-1 2004 Studies have shown that CYP2C9.1 mediated metabolism of flurbiprofen or naproxen is activated by co-incubation with dapsone. Flurbiprofen 56-68 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 24-30 15130760-4 2004 Dapsone increased the efficiency (V(m)/K(m)) of flurbiprofen 4"-hydroxylation by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5 by 8-, 31-, 47-, and 22-fold, respectively. Flurbiprofen 48-60 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 81-87 15130760-4 2004 Dapsone increased the efficiency (V(m)/K(m)) of flurbiprofen 4"-hydroxylation by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5 by 8-, 31-, 47-, and 22-fold, respectively. Flurbiprofen 48-60 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 15130760-4 2004 Dapsone increased the efficiency (V(m)/K(m)) of flurbiprofen 4"-hydroxylation by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5 by 8-, 31-, 47-, and 22-fold, respectively. Flurbiprofen 48-60 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 15130760-4 2004 Dapsone increased the efficiency (V(m)/K(m)) of flurbiprofen 4"-hydroxylation by CYP2C9.1, CYP2C9.2, CYP2C9.3, and CYP2C9.5 by 8-, 31-, 47-, and 22-fold, respectively. Flurbiprofen 48-60 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 91-97 12698304-0 2003 Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Flurbiprofen 15-27 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 53-59 12698304-1 2003 OBJECTIVE: This study was conducted to examine differences in flurbiprofen metabolism among individuals with the CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Flurbiprofen 62-74 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 113-119 12698304-4 2003 RESULTS: CYP2C9 genotype was a significant predictor of flurbiprofen metabolism and accounted for 59% of the variability in flurbiprofen AUC(0- infinity ), and approximately 50% of the variability in flurbiprofen oral clearance, formation clearance to 4"-hydroxyflurbiprofen, and the 0 to 24-h urinary metabolic ratio of flurbiprofen to 4"-hydroxyflurbiprofen. Flurbiprofen 56-68 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 9-15 12698304-4 2003 RESULTS: CYP2C9 genotype was a significant predictor of flurbiprofen metabolism and accounted for 59% of the variability in flurbiprofen AUC(0- infinity ), and approximately 50% of the variability in flurbiprofen oral clearance, formation clearance to 4"-hydroxyflurbiprofen, and the 0 to 24-h urinary metabolic ratio of flurbiprofen to 4"-hydroxyflurbiprofen. Flurbiprofen 124-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 9-15 12698304-4 2003 RESULTS: CYP2C9 genotype was a significant predictor of flurbiprofen metabolism and accounted for 59% of the variability in flurbiprofen AUC(0- infinity ), and approximately 50% of the variability in flurbiprofen oral clearance, formation clearance to 4"-hydroxyflurbiprofen, and the 0 to 24-h urinary metabolic ratio of flurbiprofen to 4"-hydroxyflurbiprofen. Flurbiprofen 124-136 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 9-15 11901091-3 2002 To this end, the kinetic profiles of three model CYP2C9 substrates (flurbiprofen, naproxen, and piroxicam) were studied using purified CYP2C9*1 (wild-type) and variants involving active site amino acid changes, including the naturally occurring variants CYP2C9*3 (Leu359) and CYP2C9*5 (Glu360) and the man-made mutant CYP2C9 F114L. Flurbiprofen 68-80 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 49-55 11901091-4 2002 CYP2C9*1 (wild-type) metabolized each of the three compounds with a distinctive profile reflective of typical hyperbolic (flurbiprofen), biphasic (naproxen), and substrate inhibition (piroxicam) kinetics. Flurbiprofen 122-134 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11901091-5 2002 CYP2C9*3 metabolism was again hyperbolic for flurbiprofen, of a linear form for naproxen (no saturation noted), and exhibited substrate inhibition with piroxicam. Flurbiprofen 45-57 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11901091-6 2002 CYP2C9*5-mediated metabolism was hyperbolic for flurbiprofen and piroxicam but linear with respect to naproxen turnover. Flurbiprofen 48-60 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 0-6 11457649-0 2001 Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. Flurbiprofen 46-58 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 30-36 11457649-1 2001 Dapsone has been shown to activate flurbiprofen 4"-hydroxylation by expressed CYP2C9 enzyme and in human liver microsomes. Flurbiprofen 35-47 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 78-84 11457649-9 2001 These dapsone plasma concentrations were within the range of concentrations producing activation of flurbiprofen metabolism by CYP2C9 in vitro. Flurbiprofen 100-112 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 127-133 9698079-0 1998 Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Flurbiprofen 126-138 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 46-65 8937439-3 1996 The major oxidative pathway in flurbiprofen metabolism is to a 4"-hydroxy metabolite, and recently we demonstrated that cytochrome P450 2C9 and its R144C variant were involved in this process (Tracy et al., Biochem Pharmacol 49: 1269-1275, 1995). Flurbiprofen 31-43 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 120-139 8937439-5 1996 In evaluating flurbiprofen as a potential probe for cytochrome P450 2C9, it is important to assess the involvement of additional P450s in this process. Flurbiprofen 14-26 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 52-71 33147873-0 2020 Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen. Flurbiprofen 196-208 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 88-94 33147873-3 2020 Flurbiprofen has absolute bioavailability of ~95% and linear pharmacokinetics in the dose range of 50-300 mg. Its absorption is considered variable and complex, often associated with double peak phenomena, and its pharmacokinetics are characterized by high inter-subject variability, mainly due to its metabolism by the polymorphic CYP2C9 (fmCYP2C9 >= 0.71). Flurbiprofen 0-12 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 332-338 31657866-6 2020 RESULTS: Experiments with human liver microsomes and primary human hepatocytes in 3D co-culture confirmed that flurbiprofen is a suitable CYP2C9 substrate. Flurbiprofen 111-123 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 138-144